Publication: 212

A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021.
      Google Scholar   
Citation:
Cancer vol 112 (8) 1772-9
Year:
2008
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pub
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
None
Children:
None
Program:
OGC
Primary Committee:
Respiratory
Sec. Committees:
   
Pharmas:
 
Grants:
CA-15083, CA-25224, CA-35101, CA-35103, CA-35113, CA-35119, CA-35195, CA-35269, CA-35415, CA-35431, CA-35448, CA-37404, CA-52352, CA-52654, CA-60276, CA-63848  
Corr. Author:
 
Authors:
                         
Networks:
 
Study
NCCTG-N0021
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords:
Adult, Aged, Aged, 80 and over, Antibiotics, Antineoplastic, Antimetabolites, Antineoplastic, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine, Disease Progression, Epirubicin, Female, Follow-Up Studies, Humans, Injections, Intravenous, Leukopenia, Male, Mesothelioma, Middle Aged, Neutropenia, Pleural Neoplasms, Quality of Life, Remission Induction, Ribonucleotide Reductases, Survival Rate, Thrombocytopenia, Treatment Outcome